AstraZeneca U.S. succession plan
Executive Summary
AstraZeneca Senior VP-U.S. Commercial Operations Tony Zook will replace U.S. President and Exec VP-North America David Brennan effective Jan. 1. Brennan has been named to succeed retiring CEO Tom McKillop (1"The Pink Sheet" Aug. 1, 2005, p. 11). Zook, who joined predecessor company Astra in 1997, previously served as AstraZeneca VP-sales; he has been leading U.S. commercial operations since Brennan was promoted to North America head in 2001 (2"The Pink Sheet" June 4, 2001, p. 32)...
You may also be interested in...
AstraZeneca’s Gut Instinct: CEO-Designate Is Nexium Brand Builder Brennan
AstraZeneca is elevating an executive integral to the commercial success of the company's proton pump inhibitor franchise with the appointment of U.S. head David Brennan as CEO
AstraZeneca
Senior VP-U.S. Commercial Operations David Brennan will become Exec VP-North America following the retirement of C.G. Johansson in July. Brennan will be succeeded by VP-Sales Tony Zook
Stalemate Over Virtual Audits In EU As Commission Tells TEAM-NB To Back Off
Notified bodies’ efforts to enhance a harmonized approach to remote audits have failed, raising questions about whether there is any avenue left to get vital devices certified by the 26 May EU MDR deadline.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: